Skip to content

A Triple-Blind, Placebo-Controlled, Randomized Clinical Trial of CANnabinoids for Drug Resistant Epilepsy in Adults and Children

This study is for children aged between 2 and 17 years who have Drug Resistant Epilepsy (DRE) to take part in a clinical research study. The primary purpose is to investigate if cannabinoids (CBD) work to reduce seizures in children with DRE, and if CBD works better alone or in combination with other cannabinoids including THC.

null

Participation Requirements

  • Sex:

    Male, Female

  • Eligible Ages:

    2 to 55

Participation Criteria

Inclusion Criteria:
You or your child may be eligible to participate in this trial if you or your child:

1. Is 2 to 17 years of age, inclusive
2. Diagnosed with Drug Resistant Epilepsy: not achieved seizure freedom, with adequate trials of 2 antiseizure medications

Doctors will also evaluate other criteria to make sure you and your child qualify for the study.
Exclusion Criteria:
You or your child may not be eligible to participate in this trial if you or your child:

- Has a diagnosis of psychogenic non-epileptic seizure
- Has recent (<30 days) change in anticonvulsant therapies
- Started ketogenic diet within 6 months
- Has vagal nerve stimulator implanted and activated within 12 months
- Has a clinically significant unstable medical condition
- Currently enrolled in a clinical study

Study Location

University of Calgary
University of Calgary
Calgary, Alberta
Canada

Contact Study Team

Study Sponsored By
University of Calgary
Participants Required
More Information
Study ID: REB24-1245